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Abstract
Introduction
The aim of this study was to evaluate radiological measurements to establish the origin of giant
cell tumours of bone.
Methods
A multi-centre retrospective review was conducted of patients with histologically confirmed
giant cell tumours of bone. Images were analysed to estimate the centre of the tumour.
Measured from the joint line, the ratio between the distance of the centre of the tumour and the
physeal scar was calculated.
Results
Ninety-five patients were included in the study. Two observers found the tumour to be arising
from the metaphyseal area in 94% - 97% of the cases. There was good agreement between the
measurements of observers (interclass correlation coefficient 0.71).
Conclusion 
Giant cell tumours of bone appear to be arising from the metaphyseal region.
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Introduction
Giant cell tumours of bone (GCTBs) are intermediate, locally destructive tumours, accounting
for approximately 5% of all primary bone tumours. Typically, young adults between the ages of
20 and 40 years are affected, with a predilection for females [1]. Malignant giant cell tumours of
bone, albeit rare, have been described, either as primary, where sarcomatous changes are
present within otherwise conventional GCTBs, or as secondary where a high-grade sarcoma
occurs at a previously treated GCTB site [2]. In approximately 1%-4% of all cases, the
development of pulmonary metastases occurs [3]. There is no consensus on factors that
increase the likelihood of pulmonary metastases occurring. However, some authors propose
that local recurrence is a risk factor for lung metastasis [4-9]. The literature generally reports
giant cell tumours of bone to be epiphyseal originating tumours [1]. However, some authors
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suggest that GCTB may, in fact, originate in the metaphysis [10-13]. Our clinical impression
also favours a metaphyseal origin of GCTB.
Giant cell tumours of bone are primarily treated with surgical resection, either by intralesional
curettage or wide resection. Intralesional curettage is often favoured, as most giant cell
tumours of bone occur peri-articularly and curettage preserves limb function. Some authors
favour wide resection to minimise local recurrence. However, these procedures have a higher
incidence of surgical complications, including infection, and limited joint function [14]. The
management of giant cell tumours of bone is challenged by high rates of local recurrence,
which, in part, is a consequence of an intraoperative residual tumour [15]. Denosumab, a
monoclonal antibody that binds to receptor activator of nuclear factor-kappa Β ligand (RANKL)
and inhibits osteoclastogenesis, can also be used in the management of GCTB. The use of
denosumab may be beneficial by reducing the size of the tumour, thereby making surgery
technically easier, and may reduce the size of any residual tumour left after surgery [16].




A multi-centre retrospective review was conducted of consecutive adult patients with a
confirmed histological diagnosis of a giant cell tumour of bone between June 2012 and May
2017 in two primary bone tumour centres. Inclusion criteria included a confirmed histological
diagnosis of a non-malignant giant cell tumour of bone and age over 18 years. Patients without
appropriate imaging (i.e., severe joint destruction or physeal scar not visible) were excluded.
Magnetic resonance imaging (MRI) images
MRI images were often obtained from outside institutions and the sequences obtained were not
standardised. However, as a minimum, a T1 sequence was obtained in all patients.
Measurements were taken from the T1 sequence that had a minimum slice thickness of 3 mm.
Images were downloaded from the picture archive and communications system (PACS),
duplicated into two separate folders, and measured independently by two observers (A and B).
Observer A was a consultant orthopaedic oncologist, and observer B was a medical student. The
method of taking measurements (Figure 1) was pre-agreed. A medical student was used as an
observer to minimise cognitive bias.
2020 Howard et al. Cureus 12(6): e8793. DOI 10.7759/cureus.8793 2 of 10
FIGURE 1: Radiological measurements
Coronal T1 MRI scan showing the measurements taken. From the joint line of the affected part of
the bone, the distance to the physeal scar (A), inferior margin of the tumour (B) and superior margin
(C) of the tumour were measured. The width of the tumour (D) was also measured. All
measurements were in pixels.
MRI: magnetic resonance imaging
Measurements
From the MRI images, the distance from the joint line to the physeal scar was measured (Figure
1A). The distance from the joint line to the inferior aspect of the tumour (Figure 1B) and the
distance from the joint line to the superior aspect of the tumour (Figure 1C) were measured.
The width of the tumour was also measured (Figure 1D).
The length of the tumour was calculated by subtracting the distance from the joint line to the
inferior margin of the tumour (Figure 1B) from the distance from the joint line to the superior
margin of the tumour (Figure 1A). The centre of the tumour, measured from the joint line, was
found by dividing the length of the tumour by two and adding it to the distance from the joint
line to the tumours inferior margin (Figure 1B). Subsequently, the ratio between the centre of
the tumour and the distance to the physeal scar was calculated (Figure 2).
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FIGURE 2: Example calculation of the centre of the tumour and
the ratio between the physeal scar and the centre of the
tumour
The figure depicts the following measurements, which are all taken perpendicular to the joint line
(orange line). 2A: the distance from the joint line to the physeal scar, 2B: the distance from the joint
line to the inferior aspect of the tumour (from the joint line), 2C: the distance from the line to the
superior aspect of the joint line, 2D: the width of the tumour. The length of the tumour was first
calculated: (Fig 2C - Fig 2B) 130 - 0. Length = 130 pixels. The centre of the tumour was calculated
by dividing the length of the tumour by 2 (65 pixels) and adding it to the distance from the joint line
to the inferior margin (2B). So 65 + 0 = 65 pixels. To calculate the ratio between the centre of the
tumour and the physeal scar, the centre of the tumour is divided by the distance from the joint line to
the physeal scar (2A). Therefore, 65 / 37 = 1.75 and, consequently, this tumour is metaphyseal in
origin.
A ratio of less than one indicates the tumour originates in the epiphysis and a ratio of greater
than one suggests a metaphyseal origin (Figure 3).
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FIGURE 3: Metaphyseal originating giant cell tumours of bone
MRI images showing examples of histologically proven giant cell tumours of bone, (2A), (2B), (2C),
(2D), which appear to be predominantly metaphyseal in origin. Red arrows highlight the location of
the lesion.
Statistical analysis
Data were analysed with R statistical software (R Foundation, Vienna, Austria). Boxplots of
ratios were created and agreement between observers was assessed with the interclass
correlation coefficient [17]. Bland-Altman plots with 95% confidence intervals were used to
assess agreement and measurement bias.
Interclass correlation coefficient values between 0.40 and 0.59 were regarded as showing fair
agreement, between 0.60 and 0.74 as good agreement and greater than 0.75 as excellent
agreement.
Results
Ninety-five patients were identified from a consecutive cohort of 195 patients that had all
required imaging available for review. One hundred patients were excluded, as the physeal scar
was not visible on images and, therefore, measurements could not be completed. Fifty-six
patients were male (59%) and 39 patients were female (41%). The median age was 35 years
(interquartile range (IQR): 27 - 47 years). Forty-four (46%) tumours were on the left side and 51
(54%) on the right side. The most common site of tumour was the distal femur in 43 (45%)
cases, followed by the proximal tibia in 36 (38%), proximal femur 4 (4%), proximal humerus 4
(4%), metacarpal 3 (3%), distal humerus 1 (1%), distal tibia 1 (1%), proximal fibula 1 (1%),
metatarsal 1 (1%) and distal radius 1 (1%).
Although roughly spherical, most tumours were slightly longer along the long axis of the bone
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(Figure 4).
FIGURE 4: Length to width ratio of giant cell tumour of bone
Boxplots to show the ratio between the maximum tumour length and tumour width of giant cell
tumours of bone. Horizontal lines represent the median and the vertical lines from the boxes
represent the quartiles of data. Dots represent extreme values of data. The tumours were roughly
spherical but were slightly longer along the long axis.
The origin of the tumour was found to be predominantly in the metaphyseal area (Figure 5).
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FIGURE 5: Tumour centre relative to physis
Boxplots to illustrate the ratio between the distance of the centre of the tumour to the physeal scar
as measured from the joint line. Horizontal lines represent the median of data. Vertical lines
represent the quartiles and dots represent extreme values of data. The ratios of the majority of the
tumours were greater than 1, indicating the origin of the tumour to be metaphyseal.
The interclass correlation coefficient for tumour length over width was 0.56 (95% CI: 0.40 -
0.68) showing only fair agreement between observers. However, the interclass correlation
coefficient for the ratio of the tumour centre to the physeal scar was 0.71 (95% CI: 0.60 - 0.80)
showing good agreement between observers. The Bland-Altman plot also shows good
agreement without bias (Figure 6).
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FIGURE 6: Bland-Altman plot for tumour centre
The Bland-Altman plot for the estimation of the ratio between the distance of the centre of the
tumour to the physeal scar as measured from the joint line. There was no bias between observers
and little variance between observers.
Using the ratio as a measure of tumour origin, one observer estimated 97% of the tumours to be
metaphyseal in origin whilst the other estimated this to be 94%.
Discussion
Our study suggests that giant cell tumours of bone are tumours originating from the
metaphyseal area. It is generally reported in the literature that giant cell tumours of bone are
epiphyseal in origin [1]. Conversely, Murphey et al. suggested that in skeletally immature
patients, GCTBs originate in the metaphysis and the open physeal plate acts as a barrier to
tumour growth [18]. Consequently, it has been suggested that GCTB may originate in the
metaphysis and spread to the epiphysis after physeal plate closure [10]. Although in our study,
all patients under the age of 18 were excluded, there was one image measured that had an open
physeal plate, which potentially alters the results from that image and is a limitation of our
study.
In a recent study by Futamura et al., the investigators calculated the vertical centre of tumours
on anteroposterior X-rays of tumours [10]. In their study cohort, 80% of tumours originated in
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the metaphysis. Our study also supports the metaphyseal origin of giant cell tumours of bone.
This opinion is strengthened by the good agreement between observers, irrespective of the level
of experience and, therefore, results are also reproducible.
However, measurements are not always easy to obtain. Not all patients had appropriate
imaging, and of the 195 consecutive patients, only 95 had suitable imaging available. Most
patients with a distal radial tumour had extensive involvement, making measurements
impossible, as the physeal scar was no longer visible. Our study only includes one patient with a
distal radial giant cell tumour of bone and this may have introduced bias.
Measurements in the distal femur and proximal tibia were usually straightforward to obtain.
However, the physis has a more complex arrangement in the proximal humerus, perhaps
explaining the larger variance in measurements in that location.
The limited spatial resolution of MRI may have caused further variance in measurements.
However, the use of ratios, rather than absolute measurements, helps to reduce this effect.
Our results show that the ratio between tumour length and tumour width is roughly equal,
indicating a spherical tumour shape. This seems to indicate equal tumour growth in all
directions. Consequently, it appears reasonable to assume a metaphyseal origin as indicated by
the measurements.
Tumour growth is supported by osteoclastic resorption of bone in all directions. However,
cartilage cannot be resorbed by the osteoclast and tumour growth stops at the subchondral
bone. From then onwards, growth can only occur in the width or proximally. Initially, pain may
not be a predominant feature. However, once the tumour has reached the subchondral bone, a
subchondral fracture is likely to occur, and the patient presents with pain.
Conclusions
Previously, giant cell tumours of bone were considered to be epiphyseal originating tumours.
From our study, measurements from MRI images found giant cell tumours of bone to be roughly
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